Learning and behavioral deficits associated with the absence of the fragile X mental retardation protein: what a fly and mouse model can teach us
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
The Fragile X syndrome (FXS) is the most frequent form of inherited mental disability and is considered a monogenic cause of autism spectrum disorder. FXS is caused by a triplet expansion that inhibits the expression of the FMR1 gene. The gene product, the Fragile X Mental Retardation Protein (FMRP), regulates mRNA metabolism in brain and nonneuronal cells. During brain development, FMRP controls the expression of key molecules involved in receptor signaling, cytoskeleton remodeling, protein synthesis and, ultimately, spine morphology. Symptoms associated with FXS include neurodevelopmental delay, cognitive impairment, anxiety, hyperactivity, and autistic-like behavior. Twenty years ago the first Fmr1 KO mouse to study FXS was generated, and several years later other key models including the mutant Drosophila melanogaster,dFmr1, have further helped the understanding of the cellular and molecular causes behind this complex syndrome. Here, we review to which extent these biological models are affected by the absence of FMRP, pointing out the similarities with the observed human dysfunction. Additionally, we discuss several potential treatments under study in animal models that are able to partially revert some of the FXS abnormalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verkerk, A. J. M. H., Pieretti, M., Sutcliffe, J. S., Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Reiner, O., Richards, S., Victoria, M. F., Zhang, F., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90397-h · Cited by 3,481 · cited 2×
“Intraspecies characteristics and differences in genetic background contribute to genetic disease variability and therefore make the generation of a biological model a difficult task; nevertheless, following the discovery of FMR1 gene in 1991 (Pieretti et al. 1991; Verkerk et al. 1991) the first animal model to study F…”
BackgroundDifferential contribution of amygdala and hippocampus to cued and contextual fear conditioning.
Phillips, R. G., & LeDoux, J. E. (1992) · Behavioral Neuroscience · doi:10.1037/0735-7044.106.2.274 · Cited by 3,292
Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Pieretti, M., Sutcliffe, J. S., Richards, S., Verkert, A. J. M. H., Holden, J. J. A., Fenwick, R. G., Warren, S. T., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90283-5 · Cited by 2,080 · cited 2×
“site, X chromosome, A site), is evident in 50% of the metaphase chromosomes of virtually all clinically affected humans (Fu et al. 1991; Bagni et al. 2012).”
BackgroundDe novo mutations in schizophrenia implicate synaptic networks
Fromer, M., Pocklington, A. J., Kavanagh, D. H., Williams, H. J., Dwyer, S., Gormley, P., Georgieva, L., Rees, E., Palta, P., Ruderfer, D. M., et al. (2014) · Nature · doi:10.1038/nature12929 · Cited by 1,617
The mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580 · cited 2×
“proposed the “mGluR theory of FXS” (Bear et al. 2004), postulating that alterations of the mGluR pathway-dependent plasticity contribute to FXS patho-”
BackgroundResultDendritic spine pathology in neuropsychiatric disorders
Penzes, P., Cahill, M. E., Jones, K. A., VanLeeuwen, J.-E., & Woolfrey, K. M. (2011) · Nature Neuroscience · doi:10.1038/nn.2741 · Cited by 1,523
Moy, S. S., Nadler, J. J., Perez, A., Barbaro, R. P., Johns, J. M., Magnuson, T. R., Piven, J., & Crawley, J. N. (2004) · Genes, Brain and Behavior · doi:10.1111/j.1601-1848.2004.00076.x · Cited by 1,522 · cited 1×
“The numbers of approaches and the time spent in proximity with each mouse are scored (Moy et al. 2004).”
BackgroundAbsence of expression of the FMR-1 gene in fragile X syndrome
Pieretti, M., Zhang, F., Fu, Y.-H., Warren, S. T., Oostra, B. A., Caskey, C. T., & Nelson, D. L. (1991) · Cell · doi:10.1016/0092-8674(91)90125-i · Cited by 1,476
De Novo Gene Disruptions in Children on the Autistic Spectrum
Iossifov, I., Ronemus, M., Levy, D., Wang, Z., Hakker, I., Rosenbaum, J., Yamrom, B., Lee, Y.-H., Narzisi, G., Leotta, A., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.04.009 · Cited by 1,446 · cited 1×
“Recently exome sequencing of samples from patients diagnosed with schizophrenia (SCZ) (Fromer et al. 2014; Purcell et al. 2014) or autism (AD) (Iossifov et al. 2012; Waltes et al. 2014) identified several mutations in genes targeted by FMRP (for review, see Fernandez et al. 2013).”
BackgroundA polygenic burden of rare disruptive mutations in schizophrenia
Purcell, S. M., Moran, J. L., Fromer, M., Ruderfer, D., Solovieff, N., Roussos, P., O’Dushlaine, C., Chambert, K., Bergen, S. E., Kähler, A., et al. (2014) · Nature · doi:10.1038/nature12975 · Cited by 1,385 · cited 2×
“nosed with schizophrenia (SCZ) (Fromer et al. 2014; Purcell et al. 2014) or autism (AD) (Iossifov et al.”
BackgroundAltered synaptic plasticity in a mouse model of fragile X mental retardation
Huber, K. M., Gallagher, S. M., Warren, S. T., & Bear, M. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122205699 · Cited by 1,349 · cited 4×
“, increased mGluRs signaling in FXS (Huber et al. 2002) many of the therapeutic strategies are based on targeting of key dysregulated mole-”
BackgroundInfluentialPrefrontal executive and cognitive functions in rodents: neural and neurochemical substrates
Dalley, J. W., Cardinal, R. N., & Robbins, T. W. (2004) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2004.09.006 · Cited by 1,329 · cited 1×
“This behavior requires intact cortical function (Dalley et al. 2004).”
Correction of Fragile X Syndrome in Mice
Dölen, G., Osterweil, E., Rao, B. S. S., Smith, G. B., Auerbach, B. D., Chattarji, S., & Bear, M. F. (2007) · Neuron · doi:10.1016/j.neuron.2007.12.001 · Cited by 979
Dendritic Spine Pathology: Cause or Consequence of Neurological Disorders?
Fiala, J. C., Spacek, J., & Harris, K. M. (2002) · Brain Research Reviews · doi:10.1016/s0165-0173(02)00158-3 · Cited by 811 · cited 1×
“Notably, dysgenesis of dendritic spines is a feature shared by several ID disorders (for review, see Fiala et al. 2002; Penzes et al. 2011; De Rubeis et al. 2012).”
BackgroundMaking memories last: the synaptic tagging and capture hypothesis
Redondo, R. L., & Morris, R. G. M. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn2963 · Cited by 792
The Fragile X Syndrome Protein Represses Activity-Dependent Translation through CYFIP1, a New 4E-BP
Napoli, I., Mercaldo, V., Boyl, P. P., Eleuteri, B., Zalfa, F., De Rubeis, S., Di Marino, D., Mohr, E., Massimi, M., Falconi, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.07.031 · Cited by 609
Self-citationThe Autistic Neuron: Troubled Translation?
Kelleher, R. J., & Bear, M. F. (2008) · Cell · doi:10.1016/j.cell.2008.10.017 · Cited by 598 · cited 1×
“…suggests that local protein synthesis regulates memory formation and cognition, two processes that rely on activity-dependent synaptic plasticity (Kang and Schuman 1996; Antion et al. 2008; Kelleher and Bear 2008; Wang et al. 2009; Ho et al. 2011; Redondo and Morris 2011; Jung et al. 2012).”
BackgroundThe paradox of cognitive flexibility in autism
Geurts, H. M., Corbett, B., & Solomon, M. (2009) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2008.11.006 · Cited by 538 · cited 3×
“with ASD (Geurts et al. 2009).”
BackgroundInfluentialSuppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP
Yan, Q. J., Rammal, M., Tranfaglia, M., & Bauchwitz, R. P. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.06.004 · Cited by 521 · cited 9×
“Using the naı̈ve courtship and memory recall assays, McBride et al. (2005) showed that dFMRP mutant flies fed with mGlu5R antagonists (MPEP, MPPG, MTPG, and LY341495) exhibit reversed social and learning behaviors.”
BackgroundInfluentialThe translation of translational control by FMRP: therapeutic targets for FXS
Darnell, J. C., & Klann, E. (2013) · Nature Neuroscience · doi:10.1038/nn.3379 · Cited by 491 · cited 3×
“Furthermore, since FMRP plays a central role as translational repressor (for review, see Bagni et al. 2012; Darnell and Klann 2013), a few other approaches have been developed”
BackgroundChronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice
Michalon, A., Sidorov, M., Ballard, T. M., Ozmen, L., Spooren, W., Wettstein, J. G., Jaeschke, G., Bear, M. F., & Lindemann, L. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.009 · Cited by 489
From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome
Bagni, C., & Greenough, W. T. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1667 · Cited by 475
Self-citationBilousova, T. V., Dansie, L., Ngo, M., Aye, J., Charles, J. R., Ethell, D. W., & Ethell, I. M. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.061796 · Cited by 465 · cited 5×
“Additionally, minocycline, thought to exert its antimicrobial effect by the inhibition of protein synthesis (Garrido-Mesa et al. 2013), restores the anxiety-like phenotype (Bilousova et al. 2009) in the Fmr1 KO mice leading to long-term improvements after drug withdrawal (Dansie et al. 2013).”
BackgroundResultInfluentialA pilot open label, single dose trial of fenobam in adults with fragile X syndrome
Berry-Kravis, E., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., Hutchison, J., Snape, M., Tranfaglia, M., Nguyen, D. V., et al. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.063701 · Cited by 411 · cited 4×
“The outcome of a clinical trial with Fenobam showed an improvement of 20% in the PPI (Berry-Kravis et al. 2009), although the mGluR5 antagonist AFQ056 (Novartis) was very recently discontinued due to the lack of positive outcome measurements (Busquets-Garcia et al.”
BackgroundInfluentialOsterweil, E. K., Krueger, D. D., Reinhold, K., & Bear, M. F. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3888-10.2010 · Cited by 384 · cited 10×
“Learning and memory Fly Puromycin, cycloheximide Protein synthesis inhibitors Bolduc et al. (2008) Fly MPEP mGluR5 antagonist McBride et al. (2005); Bolduc et al. (2008); Tauber et al. (2011); Kanellopoulos et al. (2012) Mouse CTEP Long-lasting mGluR5 inhibitor Michalon et al. (2012) Mouse Taurine GABA A agonist El Id…”
BackgroundInfluentialAltered anxiety‐related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome
Spencer, C. M., Alekseyenko, O., Serysheva, E., Yuva‐Paylor, L. A., & Paylor, R. (2005) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2005.00123.x · Cited by 349
Characterization and localization of the FMR-1 gene product associated with fragile X syndrome
Verheij, C., Bakker, C. E., de Graaff, E., Keulemans, J., Willemsen, R., Verkerk, A. J. M. H., Galjaard, H., Reuser, A. J. J., Hoogeveen, A. T., & Oostra, B. A. (1993) · Nature · doi:10.1038/363722a0 · Cited by 343 · cited 1×
“In most cases FXS is the result of loss or functional silencing of the FMR1 gene due to methylation of the CGG triplet expansion in the 5′ untranslated region of the gene (Pieretti et al. 1991; Verheij et al. 1993).”
BackgroundBerry-Kravis, E. M., Hessl, D., Rathmell, B., Zarevics, P., Cherubini, M., Walton-Bowen, K., Mu, Y., Nguyen, D. V., Gonzalez-Heydrich, J., Wang, P. P., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004214 · Cited by 328 · cited 2×
“For example, patients with FXS given Arbaclofen (STX209), an agonist of GABA B receptor, showed an improvement in social behavior (Berry-Kravis et al. 2012).”
BackgroundFragile X syndrome: causes, diagnosis, mechanisms, and therapeutics
Bagni, C., Tassone, F., Neri, G., & Hagerman, R. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63141 · Cited by 321 · cited 13×
“Because problems in communication and speech are often reported in patients with FXS (for review, see Bagni et al. 2012; Hagerman et al. 2012), communication in the Fmr1 KO mice was also investigated by evaluating the pattern of “ultrasonic vocalizations (USV).””
BackgroundInfluentialSelf-citationBhattacharya, A., Kaphzan, H., Alvarez-Dieppa, A. C., Murphy, J. P., Pierre, P., & Klann, E. (2012) · Neuron · doi:10.1016/j.neuron.2012.07.022 · Cited by 316
Schenck, A., Bardoni, B., Langmann, C., Harden, N., Mandel, J.-L., & Giangrande, A. (2003) · Neuron · doi:10.1016/s0896-6273(03)00354-4 · Cited by 316
Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice
de Vrij, F. M. S., Levenga, J., van der Linde, H. C., Koekkoek, S. K., De Zeeuw, C. I., Nelson, D. L., Oostra, B. A., & Willemsen, R. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.04.002 · Cited by 313
Paradee, W., Melikian, H. E., Rasmussen, D. L., Kenneson, A., Conn, P. J., & Warren, S. T. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00285-7 · Cited by 305 · cited 8×
“…absence of FMRP. Memory consolidation and retrieval are not affected either; both Fmr1 KO and WT mice spent more time in the target quadrant (Kooy et al. 1996; Paradee et al. 1999; Yan et al. 2004), indicating that both groups learned and remembered the initial position of the escape plat- form.”
BackgroundMethodResultInfluentialRestivo, L., Ferrari, F., Passino, E., Sgobio, C., Bock, J., Oostra, B. A., Bagni, C., & Ammassari-Teule, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504984102 · Cited by 299 · cited 3×
“However, an increase in anxiety-like behaviors (Restivo et al. 2005) in the open-field has also been reported for the Fmr1 KO mice.”
BackgroundSelf-citationLeigh, M. J. S., Nguyen, D. V., Mu, Y., Winarni, T. I., Schneider, A., Chechi, T., Polussa, J., Doucet, P., Tassone, F., Rivera, S. M., et al. (2013) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e318287cd17 · Cited by 298 · cited 1×
“Finally, minocycline administration in patients with FXS was shown to improve attention deficits, language use, and communication skills (Paribello et al. 2010; Utari et al. 2010; Leigh et al. 2013).”
BackgroundDe Rubeis, S., Pasciuto, E., Li, K. W., Fernández, E., Di Marino, D., Buzzi, A., Ostroff, L. E., Klann, E., Zwartkruis, F. J. T., Komiyama, N. H., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.06.039 · Cited by 296 · cited 2×
“…cytoplasmic interactor CYFIP1, also known as specific RAC-1 activated protein (SRA-1), (Kobayashi et al. 1998; Schenck et al. 2003) control in an activity-dependent manner actin remodeling and local protein synthesis (Napoli et al. 2008; Galy et al. 2011; De Rubeis et al. 2013; Zhao et al. 2013).”
BackgroundSelf-citationAudiogenic Seizures Susceptibility in Transgenic Mice with Fragile X Syndrome
Musumeci, S. A., Bosco, P., Calabrese, G., Bakker, C., De Sarro, G. B., Elia, M., Ferri, R., & Oostra, B. A. (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb01499.x · Cited by 289
(Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features
Peier, A. M. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.8.1145 · Cited by 285
Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice
Hayashi, M. L., Rao, B. S. S., Seo, J.-S., Choi, H.-S., Dolan, B. M., Choi, S.-Y., Chattarji, S., & Tonegawa, S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705003104 · Cited by 281 · cited 5×
“Consistently, genetic manipulation or drug treatment leading to PAK1 activity reduction (Hayashi et al. 2007; Dolan et al. 2013) correct hyperactivity (Hayashi et al. 2007; Dolan et al. 2013) and repetitive behaviors as well as reduce the frequency of seizures (Dolan et al. 2013) of mutant mice.”
BackgroundMethodInfluentialHayashi, M. L., Choi, S.-Y., Rao, B. S. S., Jung, H.-Y., Lee, H.-K., Zhang, D., Chattarji, S., Kirkwood, A., & Tonegawa, S. (2004) · Neuron · doi:10.1016/j.neuron.2004.05.003 · Cited by 280 · cited 1×
“PAK1 has been shown to antagonize the role of FMRP by reducing both spine number and the proportion of longer and thinner dendrites (Hayashi et al. 2004).”
BackgroundSensorimotor gating abnormalities in young males with fragile X syndrome and Fmr1-knockout mice.
Frankland, P. W., Wang, Y., Rosner, B., Shimizu, T., Balleine, B. W., Dykens, E. M., Ornitz, E. M., & Silva, A. J. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001432 · Cited by 275 · cited 3×
“However, in one study (Frankland et al. 2004), Fmr1 KO mice showed an excessive reaction to auditory stimuli, similar to humans (Renoux et al.”
BackgroundEpilepsy in fragile X syndrome
Berry‐Kravis, E. (2002) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.2002.tb00277.x · Cited by 271
Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486
Dolan, B. M., Duron, S. G., Campbell, D. A., Vollrath, B., Rao, B. S. S., Ko, H.-Y., Lin, G. G., Govindarajan, A., Choi, S.-Y., & Tonegawa, S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219383110 · Cited by 260 · cited 5×
“Consistently, genetic manipulation or drug treatment leading to PAK1 activity reduction (Hayashi et al. 2007; Dolan et al. 2013) correct hyperactivity (Hayashi et al. 2007; Dolan et al. 2013) and repetitive behaviors as well as reduce the frequency of seizures (Dolan et al. 2013) of mutant mice.”
BackgroundInfluentialToward Fulfilling the Promise of Molecular Medicine in Fragile X Syndrome
Krueger, D. D., & Bear, M. F. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-061109-134644 · Cited by 259 · cited 1×
“Additionally, we discuss several potential treatments under study in animal models that are able to partially revert some of the FXS abnormalities.”
BackgroundDisrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome
Ronesi, J. A., Collins, K. A., Hays, S. A., Tsai, N.-P., Guo, W., Birnbaum, S. G., Hu, J.-H., Worley, P. F., Gibson, J. R., & Huber, K. M. (2012) · Nature Neuroscience · doi:10.1038/nn.3033 · Cited by 251
p140Sra-1 (specifically Rac1-associated protein) is a novel specific target for Rac1 small GTPase
Kobayashi, K., Kuroda, S., Fukata, M., Nakamura, T., Nagase, T., Nomura, N., Matsuura, Y., Yoshida-Kubomura, N., Iwamatsu, A., & Kaibuchi, K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.1.291 · Cited by 244 · cited 2×
“In addition, recent evidence (Guo et al. 2012) indicated that Fmr1 KO mice, when studied in the radial arm maze apparatus, perform worse compared with wild-type littermates, as measured by the decreased ability of Fmr1 KO mice to preserve spatial information after food reward.”
BackgroundGalvez, R., & Greenough, W. T. (2005) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.30709 · Cited by 231
Osterweil, E. K., Chuang, S.-C., Chubykin, A. A., Sidorov, M., Bianchi, R., Wong, R. K. S., & Bear, M. F. (2013) · Neuron · doi:10.1016/j.neuron.2012.01.034 · Cited by 230 · cited 9×
“Learning and memory Fly Puromycin, cycloheximide Protein synthesis inhibitors Bolduc et al. (2008) Fly MPEP mGluR5 antagonist McBride et al. (2005); Bolduc et al. (2008); Tauber et al. (2011); Kanellopoulos et al. (2012) Mouse CTEP Long-lasting mGluR5 inhibitor Michalon et al. (2012) Mouse Taurine GABA A agonist El Id…”
BackgroundInfluentialOpen-label add-on treatment trial of minocycline in fragile X syndrome.
Paribello, C., Tao, L., Folino, A., Berry-Kravis, E., Tranfaglia, M., Ethell, I. M., & Ethell, D. W. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-91 · Cited by 223 · cited 1×
“Finally, minocycline administration in patients with FXS was shown to improve attention deficits, language use, and communication skills (Paribello et al. 2010; Utari et al. 2010; Leigh et al. 2013).”
BackgroundBehavioral and neuroanatomical characterization of the Fmr1 knockout mouse
Mineur, Y. S., Sluyter, F., de Wit, S., Oostra, B. A., & Crusio, W. E. (2002) · Hippocampus · doi:10.1002/hipo.10005 · Cited by 216 · cited 2×
“The Fragile X syndrome: clinical features Complex cognitive brain functions are affected in patients with learning and intellectual disabilities (IDs), adult onset dementias such as Alzheimer disease, aging-dependent dementias and the various amnesias.”
BackgroundInfluence of matrix metalloproteinase MMP-9 on dendritic spine morphology
Michaluk, P., Wawrzyniak, M., Alot, P., Szczot, M., Wyrembek, P., Mercik, K., Medvedev, N., Wilczek, E., De Roo, M., Zuschratter, W., et al. (2011) · Journal of Cell Science · doi:10.1242/jcs.090852 · Cited by 214 · cited 1×
“Intracellular minocycline has been shown to inhibit metalloproteinase-9 (MMP-9) involved in synaptic plasticity and dendritic structure (Michaluk et al. 2011; Janusz et al. 2013).”
BackgroundA phenotypic and molecular characterization of the fmr1‐tm1Cgr Fragile X mouse
Yan, Q. J., Asafo‐Adjei, P. K., Arnold, H. M., Brown, R. E., & Bauchwitz, R. P. (2004) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2004.00087.x · Cited by 213
Excess protein synthesis in Drosophila fragile X mutants impairs long-term memory
Bolduc, F. V., Bell, K., Cox, H., Broadie, K. S., & Tully, T. (2008) · Nature Neuroscience · doi:10.1038/nn.2175 · Cited by 211 · cited 13×
“and AGO1 may be affected in those flies (Bolduc et al. 2008).”
BackgroundInfluentialWeiler, I. J., Spangler, C. C., Klintsova, A. Y., Grossman, A. W., Kim, S. H., Bertaina-Anglade, V., Khaliq, H., de Vries, F. E., Lambers, F. A. E., Hatia, F., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407533101 · Cited by 210 · cited 6×
“Learning and memory Fly Puromycin, cycloheximide Protein synthesis inhibitors Bolduc et al. (2008) Fly MPEP mGluR5 antagonist McBride et al. (2005); Bolduc et al. (2008); Tauber et al. (2011); Kanellopoulos et al. (2012) Mouse CTEP Long-lasting mGluR5 inhibitor Michalon et al. (2012) Mouse Taurine GABA A agonist El Id…”
BackgroundInfluentialMildly impaired water maze performance in maleFmr1 knockout mice
D'Hooge, R., Nagels, G., Franck, F., Bakker, C. E., Reyniers, E., Storm, K., Kooy, R. F., Oostra, B. A., Willems, P. J., & De Deyn, P. P. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00224-2 · Cited by 208 · cited 2×
“…mice, tested using the reverse MWM or reverse T/Y-maze, needed more time to learn the new position of the platform (Bakker 1994; Kooy et al. 1996; D’Hooge et al. 1997; Bhattacharya et al. 2012), suggesting that acquisition of the new spatial information is impaired in the absence of FMRP…”
BackgroundMethodSocial behavior deficits in the Fmr1 mutant mouse
Mineur, Y. S., Huynh, L. X., & Crusio, W. E. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2005.11.004 · Cited by 177 · cited 2×
“In addition, Fmr1 KO males display reduced social interaction with novel females (Mineur et al. 2006) as well as impaired social dominance with unfamiliar mice (Spencer et al. 2005).”
BackgroundMin, W. W., Yuskaitis, C. J., Yan, Q., Sikorski, C., Chen, S., Jope, R. S., & Bauchwitz, R. P. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.09.017 · Cited by 146
Larson, J., Jessen, R. E., Kim, D., Fine, A.-K. S., & du Hoffmann, J. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2638-05.2005 · Cited by 135 · cited 1×
“FXS patients present an increased rate of cognitive impairments with age (Galvez and Greenough 2005; Larson et al. 2005).”
BackgroundPacey, L. K. K., Heximer, S. P., & Hampson, D. R. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.056127 · Cited by 133 · cited 3×
“agonists normalized hyperactivity and sensory gating defects (Pacey et al. 2009; Olmos-Serrano et al. 2011) and significantly improved conditioned learning (El Idrissi et al.”
BackgroundResultFragile X-related proteins regulate mammalian circadian behavioral rhythms
Zhang, J., Fang, Z., Jud, C., Vansteensel, M. J., Kaasik, K., Lee, C. C., Albrecht, U., Tamanini, F., Meijer, J. H., Oostra, B. A., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.06.003 · Cited by 131 · cited 2×
“the length of circadian period (Zhang et al. 2008) since shorter activity periods of wheel running were observed in the Fmr1 KO mice compared with controls.”
BackgroundDissociation of social and nonsocial anxiety in a mouse model of fragile X syndrome.
Liu, Z.-H., & Smith, C. B. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.02.066 · Cited by 112
The Fragile X mental retardation protein regulates matrix metalloproteinase 9 mRNA at synapses.
Janusz, A., Miłek, J., Perycz, M., Pacini, L., Bagni, C., Kaczmarek, L., & Dziembowska, M. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2207-13.2013 · Cited by 112
Self-citationReversal of Fragile X Phenotypes by Manipulation of AβPP/Aβ Levels in Fmr1KO Mice
Westmark, C. J., Westmark, P. R., O'Riordan, K. J., Ray, B. C., Hervey, C. M., Salamat, M. S., Abozeid, S. H., Stein, K. M., Stodola, L. A., Tranfaglia, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026549 · Cited by 110 · cited 3×
“…Lithium, SB216763 GSK-3 inhibitor Liu et al. (2011); Guo et al. (2012) Susceptibility to seizures Mouse MPEP mGluR5 antagonist Yan et al. (2005); Westmark et al. (2011); Thomas et al. (2012) Mouse Fenobam mGluR5 antagonist Vinueza Veloz et al. (2012) Mouse CTEP Long-lasting mGluR5 inhibitor…”
BackgroundUtari, A., Chonchaiya, W., Rivera, S. M., Schneider, A., Hagerman, R. J., Faradz, S. M. H., Ethell, I. M., & Nguyen, D. V. (2010) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-115.5.433 · Cited by 105 · cited 1×
“Finally, minocycline administration in patients with FXS was shown to improve attention deficits, language use, and communication skills (Paribello et al. 2010; Utari et al. 2010; Leigh et al. 2013).”
BackgroundTorrioli, M. G., Vernacotola, S., Peruzzi, L., Tabolacci, E., Mila, M., Militerni, R., Musumeci, S., Ramos, F. J., Frontera, M., Sorge, G., et al. (2008) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.32268 · Cited by 100 · cited 2×
“…absence of FMRP. Memory consolidation and retrieval are not affected either; both Fmr1 KO and WT mice spent more time in the target quadrant (Kooy et al. 1996; Paradee et al. 1999; Yan et al. 2004), indicating that both groups learned and remembered the initial position of the escape plat- form.”
BackgroundResultLong-lasting effects of minocycline on behavior in young but not adult Fragile X mice.
Dansie, L. E., Phommahaxay, K., Okusanya, A. G., Uwadia, J., Huang, M., Rotschafer, S. E., Razak, K. A., Ethell, D. W., & Ethell, I. M. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.058 · Cited by 95 · cited 1×
“Additionally, minocycline, thought to exert its antimicrobial effect by the inhibition of protein synthesis (Garrido-Mesa et al. 2013), restores the anxiety-like phenotype (Bilousova et al. 2009) in the Fmr1 KO mice leading to long-term improvements after drug withdrawal (Dansie et al. 2013).”
BackgroundZhao, L., Wang, D., Wang, Q., Rodal, A. A., & Zhang, Y. Q. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003450 · Cited by 67 · cited 2×
“In addition, recent evidence (Guo et al. 2012) indicated that Fmr1 KO mice, when studied in the radial arm maze apparatus, perform worse compared with wild-type littermates, as measured by the decreased ability of Fmr1 KO mice to preserve spatial information after food reward.”
BackgroundDe Rubeis, S., Fernández, E., Buzzi, A., Di Marino, D., & Bagni, C. (2012) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-7091-0932-8_23 · Cited by 48
Self-citation
Cited by
Steullet, P., Cabungcal, J.-H., Coyle, J., Didriksen, M., Gill, K., Grace, A. A., Hensch, T. K., LaMantia, A.-S., Lindemann, L., Maynard, T. M., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.47 · Cited by 360
A synaptic perspective of fragile X syndrome and autism spectrum Disorders.
Bagni, C., & Zukin, R. S. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.041 · Cited by 326
“This serine/threonine kinase regulates a variety of pathways involved in neurodevelopment, including neurogenesis, migration, axon growth and guidance, and synaptic plasticity (Santos et al., 2014).”
BackgroundSelf-citationDeliu, E., Arecco, N., Morandell, J., Dotter, C. P., Contreras, X., Girardot, C., Käsper, E.-L., Kozlova, A., Kishi, K., Chiaradia, I., et al. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0266-2 · Cited by 89
Puścian, A., Łęski, S., Kasprowicz, G., Winiarski, M., Borowska, J., Nikolaev, T., Boguszewski, P. M., Lipp, H.-P., & Knapska, E. (2016) · eLife · doi:10.7554/elife.19532 · Cited by 69
Bataveljic, D., Pivonkova, H., de Concini, V., Hébert, B., Ezan, P., Briault, S., Bemelmans, A.-P., Pichon, J., Menuet, A., & Rouach, N. (2024) · Nature Communications · doi:10.1038/s41467-024-47681-y · Cited by 40
“1 rescues behavioral de fi cits in Fmr1 knockout mice Individuals with FXS display a number of behavioral de fi cits including hippocampus-dependent cognitive and social impairments 1,3 , which are recapitulated in the Fmr1 KO mouse model 3 .”
Metadata
- Authors
- Santos, A. R., Kanellopoulos, A. K., & Bagni, C.
- Venue
- Learning & Memory
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2014-09-16
- Volume
- 21
- Issue
- 10
- Pages
- 543-555
- ISSN
- 1072-0502 (ISSN-L)
- 1549-5485
- OpenAlex
- W1997391739
- Cited by
- 86
- References
- 68
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.